Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K L Brayman

Showing results (1-10 of 94) with videos related to

Pageof 10
Sort By:
Molecular Medicine Today|August 27, 1999
Gene therapy strategies to facilitate organ transplantationS Deng, K L Brayman
Clinical Chemistry|December 1, 1994
FK-506 therapeutic drug monitoringL M Shaw, K L Brayman
Transactions & Studies of the College of Physicians of Philadelphia|February 26, 2005
Victor Satinsky (1912-1997) and the success of his partially occluding vascular clampM D Eisen, K L Brayman
Transplantation Proceedings|August 1, 1992
Factors leading to improved outcome following pancreas transplantation--the influence of immunosuppression and HLA matchingK L Brayman, D E Sutherland
Transplantation Proceedings|April 1, 1990
Studies of host immunomodulation and prevention of pancreatic beta cell destructionK L Brayman, A Naji, C F Barker
Clinical Therapeutics|May 24, 2000
Advances in therapeutic drug monitoring for immunosuppressants: a review of sirolimus. Introduction and overviewL M Shaw, B Kaplan, K L Brayman
Transplantation Proceedings|February 1, 1989
Thymus allografts fail to improve lymphopenia or prevent autoimmune diabetes in the BB ratK L Brayman, D Deaton, C F Barker
Clinical Chemistry|February 25, 1998
Prospective investigations of concentration-clinical response for immunosuppressive drugs provide the scientific basis for therapeutic drug monitoringL M Shaw, B Kaplan, K L Brayman
Surgical Technology International|May 8, 2015
Beta Cell Replacement Therapy in the 1990's An Overview of Pancreatic and Islet Cell TransplantationM M Levy, K L Brayman, D E Sutherland
Transplantation Proceedings|February 1, 1997
Is the glucuronide metabolite of MPA pharmacologically active?I Nowak, J Wu, K L Brayman, et al.
Pageof 10

Showing results (1-10 of 94) with videos related to

Sort By:
Pageof 10
Molecular Medicine Today|August 27, 1999
Gene therapy strategies to facilitate organ transplantationS Deng, K L Brayman
Clinical Chemistry|December 1, 1994
FK-506 therapeutic drug monitoringL M Shaw, K L Brayman
Transactions & Studies of the College of Physicians of Philadelphia|February 26, 2005
Victor Satinsky (1912-1997) and the success of his partially occluding vascular clampM D Eisen, K L Brayman
Transplantation Proceedings|August 1, 1992
Factors leading to improved outcome following pancreas transplantation--the influence of immunosuppression and HLA matchingK L Brayman, D E Sutherland
Transplantation Proceedings|April 1, 1990
Studies of host immunomodulation and prevention of pancreatic beta cell destructionK L Brayman, A Naji, C F Barker
Clinical Therapeutics|May 24, 2000
Advances in therapeutic drug monitoring for immunosuppressants: a review of sirolimus. Introduction and overviewL M Shaw, B Kaplan, K L Brayman
Transplantation Proceedings|February 1, 1989
Thymus allografts fail to improve lymphopenia or prevent autoimmune diabetes in the BB ratK L Brayman, D Deaton, C F Barker
Clinical Chemistry|February 25, 1998
Prospective investigations of concentration-clinical response for immunosuppressive drugs provide the scientific basis for therapeutic drug monitoringL M Shaw, B Kaplan, K L Brayman
Surgical Technology International|May 8, 2015
Beta Cell Replacement Therapy in the 1990's An Overview of Pancreatic and Islet Cell TransplantationM M Levy, K L Brayman, D E Sutherland
Transplantation Proceedings|February 1, 1997
Is the glucuronide metabolite of MPA pharmacologically active?I Nowak, J Wu, K L Brayman, et al.
Pageof 10